PBA
CRGX

Paradigm Biocapital Advisors’s CARGO Therapeutics CRGX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CRGX Stock Details CRGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-147,959
Closed -$3.3M – 40
2024
Q1 		$3.3M Sell
147,959
-185,374
-56% -$4.41M 0.12% 33
2023
Q4 		$7.72M Buy
+333,333
New +$5.65M 0.36% 27

Other funds holding CRGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Paradigm Biocapital Advisors's CRGX Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of CARGO Therapeutics (CRGX) in Q2 2024, closing a stake of 147,959 shares — an estimated $3.3M sold.

Paradigm Biocapital Advisors first reported a position in CRGX in Q4 2023 and held it in 2 quarters. The position peaked at $7.72M in Q4 2023. 73 funds tracked by Wall St. Rank hold CRGX as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining CARGO Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 147,959 CARGO Therapeutics shares in Q2 2024, an estimated $3.3M.
  • Paradigm Biocapital Advisors first reported a position in CARGO Therapeutics in Q4 2023 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's CARGO Therapeutics position peaked at $7.72M in Q4 2023.
  • 73 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.